CCS adapting to COVID-19 realities to support Canadians during and after the pandemic
Consolidation therapy for multiple myeloma
Consolidation therapy for multiple myeloma is given after a stem cell transplant. It’s a short course of chemotherapy that helps make the previous chemotherapy treatment and stem cell transplant work better. Consolidation therapy also helps to keep the multiple myeloma in remission for longer.
Consolidation therapy for people with multiple myeloma who have had a stem cell transplant is most often the VRD regimen. The VRD regimen uses bortezomib (Velcade), lenalidomide (Revlimid) and dexamethasone (Decadron, Dexasone).
Funding world-class research
Cancer affects all Canadians but together we can reduce the burden by investing in research and prevention efforts. Learn about the impact of our funded research.
